Subscribe
Numstocker / Shutterstock.com
3 October 2024NewsAmericasMuireann Bolger

Moderna wins reprieve in COVID-19 vaccine dispute

Alnylam backed down after judge’s patent interpretation favoured Moderna | Case is part of a spate of infringement lawsuits aimed at both Moderna and Pfizer | Plaintiff may be allowed to refile in future.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Alnylam says Moderna used patented tech to make vaccine
22 March 2022   Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.
Big Pharma
IP Life Sciences Exchange: a preview
7 November 2016   The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.


Editor's picks

Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024

Editor's picks

Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024

More on this story

Americas
Alnylam says Moderna used patented tech to make vaccine
22 March 2022   Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.
Big Pharma
IP Life Sciences Exchange: a preview
7 November 2016   The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.

More on this story

Americas
Alnylam says Moderna used patented tech to make vaccine
22 March 2022   Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.
Big Pharma
IP Life Sciences Exchange: a preview
7 November 2016   The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.

More features

Boehringer sues Indian manufacturer over diabetes drug generic
UK judge ends J&J unit’s hopes of reviving Stelara patent
‘It was like starting all over again’: Tobias Wuttke
‘This is a big problem’: The CRISPR controversy and the ‘mess’ at the heart of the EPO’s appeals boards
‘I’m breaking new ground’: Mölnlycke’s first TM attorney charts a new course
Drug approvals up but global innovation declines
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
Preventative IP for preventative pharma healthcare